Rodríguez-Antigüedad Jon, Olmedo-Saura Gonzalo, Pagonabarraga Javier, Martínez-Horta Saül, Kulisevsky Jaime
Medicine Department, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Ther Adv Neurol Disord. 2025 May 26;18:17562864251336903. doi: 10.1177/17562864251336903. eCollection 2025.
Neuropsychiatric symptoms in Parkinson's disease (PD) are highly prevalent and profoundly disabling, often emerging even before the onset of motor symptoms. As the disease progresses, these symptoms usually become increasingly impairing and are now recognized as having the greatest impact on quality of life not only for patients but also for caregivers. In recent years, there have been significant advances in the diagnosis and management of neuropsychiatric symptoms. However, there are still substantial gaps in therapeutic approaches and algorithms, with limited pharmacological and nonpharmacological treatment options currently available. One of the main reasons for this is the complex molecular and neural bases of these symptoms, which involve both dopaminergic and nondopaminergic neurotransmission systems and extend far beyond the nigrostriatal pathway. As a result, the drugs currently recommended for treating neuropsychiatric symptoms in PD are few and supported by limited evidence. In this context, the experience of the treating neurologist remains critical in selecting the most appropriate individualized therapy. The aim of this paper is to review the available therapeutic options and provide an overview of current research efforts, particularly those focusing on pharmacological treatments.
帕金森病(PD)中的神经精神症状非常普遍且严重致残,常常在运动症状出现之前就已出现。随着疾病进展,这些症状通常会越来越严重,现在被认为不仅对患者而且对护理人员的生活质量都有最大影响。近年来,神经精神症状的诊断和管理取得了重大进展。然而,治疗方法和算法仍存在很大差距,目前可用的药物和非药物治疗选择有限。造成这种情况的主要原因之一是这些症状复杂的分子和神经基础,其涉及多巴胺能和非多巴胺能神经传递系统,且远远超出黑质纹状体通路。因此,目前推荐用于治疗PD神经精神症状的药物很少,且证据有限。在此背景下,主治神经科医生的经验在选择最合适的个体化治疗方面仍然至关重要。本文的目的是回顾现有的治疗选择,并概述当前的研究工作,特别是那些专注于药物治疗的研究。